Introduction {#S1}
============

The adaptive immune response to infection includes both a cellular and humoral component. The cellular immune response is mediated by T cells, which play a role in direct killing of virus-infected cells via cytotoxic (CD8) T cells as well as helping to direct the overall immune response through helper (CD4) T cells. The humoral immune response also includes CD4 T cells which assist B cells to differentiate into plasma cells and subsequently produce antibodies specific to a targeted antigen. As T cells are involved in the early identification and clearance of viral infections by both cellular and humoral immunity, they are a desirable target for assessing SARS-CoV-2 exposure ([@R14], [@R32], [@R22], [@R28], [@R2]).

Healthy adults have ^\~^10^12^ circulating T cells expressing approximately 10^7^ unique TCRs ([@R24]). This diversity allows the full repertoire of T cells to potentially recognize a wide variety of peptide antigens displayed by HLA molecules on the surface of cells. When a naíve T cell is activated in response to recognition of a cognate antigen presented by a specialized antigen presenting cell, it undergoes clonal expansion, resulting in an exponentially increasing number of genetically identical T cells. Due to the extreme sequence diversity possible among TCR rearrangements, particularly the TCR-beta chain, each observed TCR sequence is essentially a unique tag for a clonal lineage of T cells. Thus, the number of copies of each TCR sequence represents the number of T cells in that clonal lineage and provides information about the natural history of T-cell clonal expansions. Measuring the cellular immune response can provide a view into the state of the overall immune response, and several qualities of the adaptive cellular immune response suggest a T-cell-based assay may fulfill unmet clinical needs. In general, the T-cell immune response is: 1) Sensitive: T cells detect even a very small amount of antigen; 2) Specific: TCRs bind only to specific antigens; 3) Naturally amplified: T cells proliferate and clonally expand upon recognition of small quantities of specific antigen via their TCRs; 4) Systemic: T-cell clones circulate throughout the body in the blood; and 5) Persistent: a subset of T cells are maintained following clonal contraction in long term memory ([@R26], [@R8], [@R7], [@R12], [@R9]). The T-cell response is typically the first component of the adaptive immune response that can be measured, within days from initial pathogen exposure, and after clonal expansion and transition into memory can persist for years even when antibodies become undetectable. In the context of coronavirus infections, persistent T cells specific for SARS-CoV-1 have been routinely detected in studies in the years following the initial SARS outbreak ([@R21], [@R29]), including at least a decade after initial infection ([@R18]). Subjects show lasting memory T-cell populations to SARS-CoV-1 even as IgG antibodies and peripheral memory B cells become undetectable in a majority of convalescent subjects ([@R29]). Similarly, T cells responsive to the Middle East respiratory syndrome (MERS) coronavirus were observed in the absence of detectable antibodies ([@R33]).

Standard methods to assess the cellular immune response to a pathogen are based on T-cell recognition of target antigens. Conventional immune monitoring assays, including ELISpot and ICS, rely on functional T-cell responses and require live T cells, thus limiting standardization and throughput. The emergence of the COVID-19 pandemic has generated the urgent need for a scalable molecular assay to assess the T-cell response to SARS-CoV-2. In response, Adaptive Biotechnologies and Microsoft have applied previously developed platforms to create immunoSEQ^®^ T-MAP™ COVID, a TCR sequence-based approach to quantitatively assess the T-cell response to SARS-CoV-2. This approach utilizes a multiplexed experimental platform to interrogate T-cell repertoires with large numbers of query antigens to identify SARS-CoV-2-specific TCRs in the context of HLA ([@R15]). We have deeply characterized 61 COVID-19 subject samples against 545 potential peptide antigens to profile the CD8 immune response. We have further sequenced 1,015 blood samples from 827 COVID-19 cases with immunoSEQ^®^ in order to identify a robust set of SARS-CoV-2 specific CD4 and CD8 TCRs from a fixed number of blood cells ([@R5], [@R25]). All of these data are available as part of the public ImmuneCODE data release at <https://clients.adaptivebiotech.com/pub/covid-2020> ([@R20]).

Taken together, these approaches allow the development of a map between TCR sequences and SARS-CoV-2 specific antigens, as well as the identification of public SARS-CoV-2 specific TCRs shared across individuals. This approach allows us to characterize many of the antigens involved in a T-cell immune response. We also capture a measure of the clonal breadth (the estimated proportion of distinct T-cell clonal lineages in a repertoire that are SARS-CoV-2 specific) and depth (related to the relative frequency of SARS-CoV-2-specific T-cell clones in a repertoire), as well as the dynamics of the cellular immune response to a SARS-CoV-2 infection over time. The exact antigens targeted are elucidated for several of these clones, which may allow for mapping a vaccine response in comparison to the response in a natural infection ([@R8]). Moreover, a collection of public SARS-CoV-2 TCRs form a robust diagnostic for recent or past infection of SARS-CoV-2. We report initial findings that the T-cell response is durable for at least 3 months post infection, which is the current limit of the samples available to assess.

Results {#S2}
=======

Identification of SARS-CoV-2-specific TCRs from COVID-19 subjects {#S3}
-----------------------------------------------------------------

To directly characterize the CD8 T-cell response to SARS-CoV-2, we applied MIRA ([M]{.ul}ultiplex [I]{.ul}dentification of T-cell [R]{.ul}eceptor [A]{.ul}ntigen Specificity), which maps TCRs to antigens at high scale and specificity ([@R15]). 545 query peptides derived from across the SARS-CoV-2 genome were selected from HLA-I NetMHCpan predictions across multiple representative HLA types ([@R3], [@R19]). These peptides were synthesized and assigned either individually or as groups of related peptides to one of 269 unique MIRA pools or "addresses" as described in the methods.

MIRA was performed on T cells derived from PBMCs collected from 3 acutely infected and 58 convalescent COVID-19 subjects. Overall, 23,179 unique SARS-CoV-2 specific CD8 TCRs were identified 25,442 times across all experiments. The identified TCRs mapped to 260 of the 269 pools, representing antigens from across the viral proteome ([Figure 1a](#F1){ref-type="fig"},[b](#F1){ref-type="fig"}). Strong immune responses (assessed by total number of TCRs) as well as common immune responses (assessed by number of subjects with response to an antigen) were observed across the viral proteome.

We then explored the diversity of TCRs identified by MIRA across all the subjects by protein and by antigen. [Figure 2a](#F2){ref-type="fig"} shows a clustergram of the protein-level response by subject, normalized to show the fraction of total TCRs identified per target. [Figure 2b](#F2){ref-type="fig"} shows a similar analysis at the antigen-level, showing the 50 antigen locations with the most total TCRs observed across all subjects. A complete representation of the TCRs by antigen location is given in [Supporting Table S1](#SD1){ref-type="supplementary-material"}. Preliminary analyses indicate these response data were heavily skewed by antigen, with 70% of all TCR mappings accounted for by 14 antigen pools ([Supporting Table S1](#SD1){ref-type="supplementary-material"}). Similarly, responses to 8 antigens were observed in over half of the COVID subject MIRAs, suggesting these epitopes are frequently targeted during natural infection ([Table S1](#SD1){ref-type="supplementary-material"}).

Our results suggest that in many subjects the immune response is dominated by a large number of distinct T cells against just a few epitopes, which may result from distinct HLA presentation. [Figure 2a](#F2){ref-type="fig"} shows about 30% of subjects (first cluster, blue) have a predominantly ORF1ab-directed response in terms of total distinct T-cell clones, which is primarily explained by the single peptide HTTDPSFLGRY. Similarly, about 35% of subjects (fifth cluster, red) have a predominantly nucleocapsid phosphoprotein response, represented by at least two dominant antigen positions. Another cluster (third cluster, green) shows a more distributed response across multiple proteins/antigens while the second cluster in orange has stronger surface glycoprotein response.

An HLA association analysis to the identified antigen-level clusters ([Figure 2b](#F2){ref-type="fig"}) was performed using Fisher's exact test. The second cluster (orange) is primarily explained by TCRs associated with ORF1ab:5171-5203 (single peptide HTTDPSFLGRY). There are 12 subjects in this cluster with HLA typing available; all 12 have HLA-A\*01:01 demonstrating significant enrichment (p=2e-10) for this allele considering only 13 total subjects have this allele in this dataset. This peptide is predicted to be presented by HLA-A\*01:01 by NetMHCpan. Similarly, the fourth cluster (green) contains 11 cases with HLA typing and all 11 subjects (out of 13 in this dataset) have HLA-B\*07:02 (p=4e-9). There are two overlapping peptides in this address (LSPRWYFYY and SPRWYFYYL); the latter is predicted to be presented by HLA-B\*07:02 by NetMHCpan. Beyond this cluster-focused analysis, putative HLA restriction has been attributed to each of these pools using a Mann-Whitney's U test over the number of mapped TCRs per experiment ([Supporting Table S2](#SD1){ref-type="supplementary-material"}), identifying 41 strong associations between antigens and HLA alleles. For 18 alleles, we identified at least one putative immunodominant epitope, which we defined as an HLA-antigen pair for which at least 50% of individuals with that allele responded to the antigen (see [Figure 1c](#F1){ref-type="fig"} for details and definitions). These results are consistent with other recent reports of strong HLA-dependent CD8 T cell response to specific antigens ([@R17], [@R11]). These assignments and emerging immunodominance hierarchies will be further explored in later work as we continue to run MIRA on cases and controls.

Overall, these results suggest that the basis of an individual immune response is heterogeneous and influenced by HLA background; some subjects show large response to just a few antigens from SARS-CoV-2 while others show a broader response. This analysis also identifies a short-list of highly immunogenic antigens to focus on for further characterizing the CD8 T cell response across individuals. We are generating more data to extend these results, as well as beginning to add in class II restricted antigens to profile COVID-19 subjects' CD4 T cell responses.

Identifying shared SARS-CoV-2-associated TCRs across the population {#S4}
-------------------------------------------------------------------

While the diversity of TCR recombination means that most TCR responses are "private" and will be infrequently seen in other individuals, a part of the T-cell response to a disease is "public" with the same amino acid sequences observed in many individuals, particularly in shared HLA backgrounds ([@R31]). Such disease-associated TCRs can be identified using a case/control design, as previously described for cytomegalovirus ([@R10]).

To this end, 1,015 samples from individuals currently or previously infected with SARS-CoV-2 were collected as part of the ImmuneCODE project ([@R20]). Immunosequencing was performed to sample the TCR repertoires as described in Methods. Additionally, 3,500 repertoires from our database processed prior to March 2020 were identified as controls (see [Supporting Table S3](#SD2){ref-type="supplementary-material"} for cohort summaries). A lower T cell fraction (suggesting lymphopenia) was observed in a number of the COVID-19 cases compared to healthy immune repertoires consistent with prior reports ([@R4]) ([Supporting Figure S1](#SD2){ref-type="supplementary-material"}). Public COVID-19 associated TCRs, which we call "enhanced sequences", were then identified using Fisher's exact test, as described in the methods.

As a pilot study, enhanced sequences were identified using two cohorts, the DLS (from New York, USA) and NIH/NIAID (from Italy) cohorts, comprising a total of 483 cases, with 1,798 pre-March 2020 controls. A total of 1,828 enhanced sequences were identified from this first data set which collectively distinguish cases from controls ([Figure 3a](#F3){ref-type="fig"}). To establish high confidence in the enhanced TCR sequences identified for SARS-CoV-2, sequence identification was also performed independently for each of these two cohorts. A total of 309 enhanced sequences from the earlier set of 1,828 were identified independently across both studies. This degree of overlap in distinct populations demonstrates the generality of the signal that has been discovered, while also pointing to the opportunity that additional data have to identify more SARS-CoV-2 associated sequences. Notably, these enhanced sequences were also substantially enriched in our other held-out cohorts, which totaled 397 cases from three additional cohorts (ISB, H12O and BWNW) and 1,702 additional controls ([Figure 3b](#F3){ref-type="fig"}).

If these public associated enhanced sequences are SARS-CoV-2 specific, then a subset of them should overlap with the antigen-specific TCRs identified by the MIRA experiments. We identified a total of 368 exact matches to 59 different enhanced sequences from the set of 1,828 identified above. There were also 810 matches (from 394 distinct TCRs) to sequences that were only one amino acid change away (with identical V-gene and J-gene assignments) from 68 distinct enhanced sequences. Of the 59 different enhanced sequences with any exact matches, 36 (61%) were mapped to the HTTDPSFLGRY peptide from ORF1ab, with the remaining 23 mapping to 11 other antigen locations from across the proteome including two other ORF1ab addresses, four surface glycoprotein addresses, two nucleocapsid phosphoprotein addresses, and one each from ORF6, ORF10, and the envelope protein (see [Supporting Table S1](#SD1){ref-type="supplementary-material"}). Including near neighbors and other sequence-based clusters of TCRs would expand this count.

Public disease-associated TCRs predict the breadth and depth of the antigen-specific T-cell response {#S5}
----------------------------------------------------------------------------------------------------

To further explore the relationship between public disease-associated TCRs and largely private antigen-specific TCR datasets identified by MIRA, repertoire sequencing was performed on the COVID MIRA donors using the immunoSEQ assay. Although the current MIRA experiments are limited to CD8 T cells specific to the 545 HLA-I presented peptides in the MIRA panel, intersecting a donor's MIRA-mapped TCRs with their immunoSEQ repertoire provides a lower bound estimate on the proportion of T cells in a subject that have likely expanded in response to SARS-CoV-2. Two specific quantities are of interest: the *clonal breadth* of the TCR repertoire, defined as the proportion of all unique TCR (DNA) clones that are SARS-CoV-2 specific; and the *clonal depth* of the TCR repertoire, related to the overall proportion of T cells that are SARS-CoV-2 specific (see [Methods](#S10){ref-type="sec"} for precise definition).

Across 51 samples with paired immunosequencing and COVID MIRA data, we observed a remarkable concordance between either the breadth ([Figure 4a](#F4){ref-type="fig"}; Spearman rho = 0.62, p = 2e-6) or depth ([Figure 4b](#F4){ref-type="fig"}; Spearman rho = 0.67, p = 6e-8) of an individual's antigen-specific response as estimated by MIRA and that of the disease-specific response as estimated through public enhanced sequences. Notably, both clonal depth and breadth as measured by an individual's MIRA response is typically an order of magnitude higher than that estimated by public clones, highlighting the extent to which MIRA is able to identify disease-associated TCRs, in addition to mapping TCRs to specific antigens. Nevertheless, for a small number of subjects, the clonal breadth and depth as estimated by public disease-specific clones is substantially higher than what is estimated by MIRA, likely indicating the role of CD4 T cells as well as CD8 T cells specific to antigens not included in the panel.

MIRA-identified TCRs from an individual experiment are largely private ([Supporting Figure S2](#SD2){ref-type="supplementary-material"}), but the scale of data from MIRA should enable identification of antigen-specific TCR patterns that generalize to new individuals ([@R7]; [@R12]). While those efforts advance, the high concordance between public enhanced sequence and MIRA defined breadth and depth provides a useful means of estimating these quantities in large populations.

Analyzing T-cell response dynamics to SARS-CoV-2 {#S6}
------------------------------------------------

As the T-cell response typically expands in the days following infection, then contracts to a steady memory state following clearance of viral antigen, the clonal breadth and depth should follow a similar trajectory. To test this hypothesis, the 1,015 COVID-19 case samples were binned based on days since PCR-confirmed diagnosis with separate plots shown for the training and holdout sets used to discover this set of enhanced sequences ([Figure 5](#F5){ref-type="fig"}). As expected, both breadth and depth indicate significant expansion of the T-cell response in a majority of subjects at time of diagnose relative to healthy controls. As time progresses, both breadth and depth increase, reaching a peak in the 8-14 day and 15-28 day bins, then contracting slightly. Notably, both the 29-42 day and 43+ day bins show noticeably higher SARS-CoV-2-specific breadth and depth compared to controls, indicating the public enhanced sequences persist following presumed antigen clearance.

Public enhanced TCR sequences are highly specific in diagnosing current and past SARS-CoV-2 infection {#S7}
-----------------------------------------------------------------------------------------------------

The significant expansion in SARS-CoV-2 specific clonal breadth and depth indicate that public enhanced sequences may constitute a useful biomarker for diagnosing past or present SARS-CoV-2 infection. Therefore, a simple logistic regression model was trained based on clonal breadth to separate cases from controls. As above, we initially used the DLS and NIFI/NIAID cohorts, with a subset of controls, for model training and then tested on a holdout set of 276 distinct case samples (with days from diagnosis information) and 1,702 pre-COVID-19 negative controls from other cohorts. Overall, the model was highly sensitive and specific in diagnosing current or past SARS-CoV-2 infection ([Supporting Table 4](#SD2){ref-type="supplementary-material"}). Using a target specificity of 99.8% across the 1,702 controls, the classifier demonstrates 77.4% sensitivity at 0-2 days post diagnosis (dpd) and 89.6% sensitivity at 3-7 dpd, further rising to 100% at 8-14 dpd. Notably, there is some reduced signal at 2-4 weeks from diagnosis; preliminary evidence suggests the negative cases are predominantly severe COVID-19 cases who die or are in the ICU, although further characterization with additional clinical / treatment data is required. Over a month after diagnosis, sensitivity for this first model is around 92-94%. We also investigated the model's performance on later convalescent samples. From a separate set of 49 subjects whose blood was drawn ranging from 0-1 months, 1-2 months, and 2+ months from end of symptoms, there was ^\~^90% sensitivity across all three of these time ranges suggesting a persistent T-cell signature after clearance of infection. The model performance is also robust to potential confounders such as age and sex ([Supporting Figure S3](#SD2){ref-type="supplementary-material"}).

Both the enhanced sequence identification and logistic regression parameter estimates should improve with additional training data. A classifier was trained with 784 unique cases across the five COVID-19 cohorts as well as 2,448 controls, using five-fold cross-validation to assess performance ([Table 1](#T1){ref-type="table"}). This model identifies a total of 4,470 enhanced sequences, more than double what was used in the initial model reported above, and increases sensitivity across later time points including reaching 98+% a month or more from initial diagnosis. We are presently generating immunosequencing data on over a thousand additional samples and will continue to improve the classifier and further characterize its potential clinical utility.

Discussion {#S8}
==========

We have described an approach that uses fine mapping of TCR sequences to hundreds of antigens in conjunction with statistical association of over a thousand public enhanced sequences to track the breadth and depth of the cellular immune response to SARS-CoV-2. This immunoSEQ T-MAP COVID approach utilizes a small volume (1-2 milliliters) of whole blood and is compatible with most standard collection methods. It reliably and reproducibly identifies and tracks SARS-CoV-2 specific T-cell clones soon after infection and for months after recovery for most subjects based on currently available samples and data. The map for CD4 T cells is currently being generated through the same combination of MIRA and case/control experiments and will be reported on alongside our ImmuneCODE public data resource.

There are many advantages of the molecular assay presented as compared to standard techniques such as ELISpot for assessing cellular immune response. The biggest advantage is that standard functional assays require live cells and the results vary depending on how the sample was handled, stored and transported. The T-cell molecular assay used here is based on DNA, which is highly stable, and probes T cells with resolution down to 1/1,000,000 cells whereas functional assays are usually only sensitive down to 1/10,000 cells. The approach assesses T cells sampled randomly from blood and, unlike functional assays, is not restricted to reagent-limited subcompartments of the cellular immune response.

Although functional T-cell assays are challenging to perform, in the hands of experts their use has led to many important findings about the cellular immune response to SARS-CoV-2. This includes early profiles of the immunoreactivity of different pools of SARS-CoV-2 antigens to CD4+ and CD8+ T cells and identification of potential cross-reactive T cells to SARS-CoV-2 in healthy individuals ([@R14], [@R32], [@R17], [@R11]). Other studies have revealed strong associations between the T-cell response and disease severity (for review, see [@R30] and [@R6]). Evidence has also emerged in a number of independent studies demonstrating detectable T-cell responses in PCR-confirmed individuals in mild or asymptomatic cases where serology was not initially detected or in those who later serorevert ([@R28], [@R22]).

This manuscript recapitulates some of these findings while also adding greater scale and resolution to the emerging picture of the T-cell response. While some other antigen stimulation approaches provide an aggregated result for how a pool of antigens may respond, MIRA allows characterization of hundreds to thousands of individual antigen addresses at the same time, associating tens of thousands of TCRs to specific antigens. Here we also demonstrated that through population scale sequencing of immune repertoires, public TCR sequences to SARS-CoV-2 can be identified that make up a shared immune response. These sequences, in combination with the MIRA data, allow characterization of disease- and antigen-specific responses including the breadth and depth of the overall cellular response to a viral infection.

Assessing T cell responses still has some challenges to be addressed in future work. As previously discussed, the MIRA results here describe the CD8 T-cell response and more work (underway) is needed to characterize the CD4 T-cell response. Also, despite including several hundred peptides in our initial CD8 T-cell panels including some of the strongest predicted binders, these likely represent just a fraction of the antigens presented in different HLA contexts. HLA diversity is a key part of the adaptive immune response; we have used large, diverse study cohorts to account for this variation, but we continue to collect more data in an effort to fill out the map for rare HLA alleles.

The importance of characterizing the cellular immune response has applications in development of therapeutics and vaccines as well as in clinical evaluation of exposure or response to SARS-CoV-2. One potential translational application of this approach is to identify and track the T-cell responses against immunogenic, virus-specific epitopes as a possible correlate of protection. Our results suggest that natural immune responses include responses to targets of current vaccines like the surface glycoprotein (spike), but also include strong or stronger responses to antigens from other viral proteins depending on HLA context consistent with other reports such as ([@R14], [@R11]). Another translational approach is to develop a T-cell based diagnostic to identify individuals with recent or past infection. The data presented here suggest frequent and persistent TCRs are elevated as far out as we have measured (^\~^100 days). This biologic observation supports the development of a TCR-based clinical diagnostic to broadly identify past exposure, especially in individuals in whom the antibody response is delayed, is muted, or wanes.

The scientific community has rapidly developed and deployed many tools to characterize the immune response to SARS-CoV-2 in an effort to aid the development of diagnostics and treatments for COVID-19. Future success in controlling and containing the current pandemic will rely on a complete picture of the biology of disease and treatment response. The development of a reproducible, high-throughput, high-resolution molecular approach to assess the T-cell response will serve to fill an important unmet need in characterizing the adaptive immune response to exposure to SARS-CoV-2 antigens.

Data Availability {#S9}
=================

As part of the ImmuneCODE data resource ([@R20]), the COVID-19 MIRA data and COVID-19 study immunosequencing data are freely available for analysis and download from the Adaptive Biotechnologies immuneACCESS site under the immuneACCESS Terms of Use at <https://clients.adaptivebiotech.com/pub/covid-2020>.

Methods {#S10}
=======

Clinical sample collection: {#S11}
---------------------------

Samples were collected based on each institution's study protocol, as reviewed by their Institutional Review Board. From all sources, whole blood samples were collected in K2EDTA tubes and were stored until being shipped to Adaptive as frozen whole blood, isolated PBMC or DNA extracted from either blood or PBMCfor immune profiling analyses via the immunoSEQ Assay and/or MIRA.

Samples provided by the NIAID were collected under approval by Comitato Etico Provinciale (protocol NP-4000), and by Comitato Etico, Ospedale San Gerardo Monza (protocol COVID-STORM). The study includes collection of discarded samples from clinically-indicated collection of blood samples obtained from patients who were admitted at ASST Spedali Civili Brescia following positive nasopharyngeal swab for SARS-CoV-2 infection.

Samples provided by Hospital 12 de Octubre were collected under approval by Comite Etico del Hospital 12 de Octubre, Madrid IC (protocol 20/161)

Samples provided by Swedish-ISB were collected under approval by the Providence St. Joseph's Health system IRB (STUDY2020000175). Study participants were recruited at clinics associated with Swedish Medical Center with a confirmed diagnosis by SARS-CoV-2 PCR or persons under investigation (with PCR pending) with \>3 diagnostic criteria. SARS-CoV-2 PCR was performed at enrollment to confirm diagnosis.

Whole blood samples from DLS (Discovery Life Sciences, Huntsville, AL) were collected under Protocol DLS13 for collection of remnant clinical samples. All DLS subjects had tested positive for SARS-CoV-2 viral exposure by an Abbott RealTime SARS-CoV-2 RT-PCR assay.

From Bloodworks Northwest (Seattle, WA), volunteer donors recovered from COVID-19 were consented and collected under the Bloodworks Research Donor Collection Protocol BT001. Samples were processed for PBMC and donor data reported by the Biological Products division of Bloodworks NW under standard operating procedures. Inclusion criteria for samples collected by Bloodworks included age of at least 18 years old, weight of more than 110 lbs, a diagnosis of SARS-CoV-2 infection, at least 28 days since positive screening or days since last symptoms or a negative SARS-CoV-2 PCR test, and a provision of informed consent to participate in the study.

Controls were selected from primarily healthy controls drawn before 2020 by Diagnostic Laboratory Services, as well as other non-COVID studies. These samples are presumed negative and include collections during seasons with high prevalence of vaccination against, and/or infection with, the influenza A/B viruses and seasonal coronavirus(es) in order to exclude potential cross-reactivity.

Viral peptide selection: {#S12}
------------------------

Using the NCBI genome reference for SARS-CoV-2 (RefSeq accession: NC_045512.2), a list of candidate 9-10AA long peptides from across the whole viral genome was identified based on predicted affinity (\<1% rank) using NetMHCpan version 4.1 ([@R3]; [@R19]) to common HLA-A and -B alleles as determined in the Allele Frequency Net Database ([@R13]). An additional 121 peptides were added to this list from ([@R1]), which identified candidate epitopes conserved between SARS-CoV-1 and SARS-CoV-2 and optimized for global HLA coverage. The final set of peptides included candidate epitopes for most common HLA alleles across the globe: A\*01:01, A\*02:01, A\*02:07, A\*03:01, A\*ll:01, A\*23:01, A\*24:02, A\*31:01, A\*33:01, A\*33:03, A\*68:01, B\*07:02, B\*08:01, B\*13:01, B\*15:01, B\*15:02, B\*18:01, B\*27:05, B\*35:01, B\*40:01, B\*44:02, B\*46:01, B\*51:01, B\*58:01, C\*14:02, C\* 15:02. Peptides were synthesized by GenScript (Piscataway, NJ). The complete list of peptides is in [Table S1](#SD1){ref-type="supplementary-material"}.

The 545 peptides were then pooled in a combinatorial fashion as described previously ([@R15]); peptides that were overlapping or in close proximity in the viral proteome were grouped together into antigen sets. Each antigen set was then placed in a subset of 6 unique pools out of 11 pools; hereto after referred to as its occupancy. In order to estimate an empirical false discovery rate and gauge assay quality, we purposefully left \> 40% of the unique occupancies empty to assess the rate at which clones are spuriously sorted and detected in 6 pools with no query antigen present.

Phylogenetic context of candidate epitopes was assessed using a customized BLAST database of 55 RefSeq coronavirus genomes across the Coronaviridae family ([@R27]). BLAST searches were optimized for short sequence queries using the "-task blastp-short" argument and all full-length, exact matching TCRs were used to assess the phylogenetic placement of each candidate epitope. Using the taxonomic annotations available from the NCBI taxonomy browser, the most recent common ancestor was defined as the most recent taxonomic node shared by all terminal taxa that shared an exact match to the epitope. Each epitope was also assessed for its homology to each of 4 endemic human coronaviruses: Human coronavirus 229E, Human coronavirus HKU1, Human coronavirus NL63, and Human coronavirus OC43 in order to explore the role of cross reactivity in T cell responses.

Antigen stimulation experiments (MIRA): {#S13}
---------------------------------------

Antigen-specific TCRs were identified using the Multiplex Identification of T-cell Receptor Antigen Specificity (MIRA; [@R15]). For these MIRA from 61 COVID-19 subjects, T cells from PBMC were first expanded with anti-CD3 (Biolegend clone OKT3, San Diego, CA) at 30 ng/ml, IL-2 (Biolegend, San Diego, CA) at 20 ng/ml, and IL-15 (Biolegend, San Diego, CA) at 5 ng/ml for 8-13 days. Expanded memory cells were then stimulated by peptide pools at 37°C for ^\~^18 hours. Replicate wells of cells were harvested from the culture and pooled and then stained with antibodies for analysis and sorting by flow cytometry. Cells were then washed and suspended in PBS containing FBS (2%), 1mM EDTA and 4,6-diamidino- 2-phenylindole (DAPI) for exclusion of non-viable cells. Cells were acquired and sorted using a FACS Aria (BD Biosciences) instrument. Sorted antigen-specific (CD3^+^CD8^+^CD137^+^) T cells were pelleted and lysed in RLT Plus buffer for nucleic acid isolation. Analysis of flow cytometry data files was performed using FlowJo (Ashland, OR).

RNA was then isolated using AllPrep DNA/RNA mini and/or micro kits, according to manufacturer's instructions (Qiagen). RNA was reverse transcribed to cDNA using Vilo kits (Life Technologies), and TCRβ amplification performed using the immunoSEQ assay described below.

After immunosequencing, we examined the behavior of T-cell clonotypes by tracking read counts across each sorted pool. True antigen-specific clones should be specifically enriched in a unique occupancy pattern that corresponds to the presence of one of the query antigens in 6 pools. We have reported on methods to assign antigen specificity to TCR clonotypes previously ([@R15]). In addition to the previously published methods, we also developed a non-parametric Bayesian model to compute the posterior probability that a given clonotype is antigen specific. This model uses the available read counts of TCRs to estimate a mean-variance relationship within a given experiment as well as the probability that a clone will have zero read counts due to incomplete sampling of low frequency clones. Together, this model takes the observed read counts of a clonotype across all 11 pools and estimates the posterior probability of a clone responding to all possible 11 choose 6 addresses and an additional hypothesis that a clone is activated in all pools (truly activated, but not specific to any of our query antigens). To define antigen specific clones, we identified TCR clonotypes assigned to a query antigen from this model with a posterior probability ≥ 0.7.

Immunosequencing of TCR repertoires: {#S14}
------------------------------------

For blood or PBMC samples, genomic DNA was extracted from either peripheral blood mononuclear cells or from peripheral blood samples using the Qiagen DNeasy Blood Extraction Kit (Qiagen). As much as 18 μg of input DNA was then used to perform immunosequencing of the CDR3 regions of TCRβ chains using the ImmunoSEQ Assay. Briefly, input DNA was amplified in a bias-controlled multiplex PCR, followed by high-throughput sequencing. Sequences were collapsed and filtered in order to identify and quantitate the absolute abundance of each unique TCRβ CDR3 region for further analysis as previously described ([@R24], [@R25], [@R5]). In order to quantify the proportion of T cells out of total nucleated cells input for sequencing, or T cell fraction, a panel of reference genes present in all nucleated cells was amplified simultaneously ([@R23]).

Characterization of the T-cell response with MIRA {#S15}
-------------------------------------------------

In two separate analyses, each donor's response to the antigens presented by the MIRA panel was summarized by the fraction of T cells responding to each protein, or to each antigen. Donors were clustered with average-linkage hierarchical clustering into five clusters (number of clusters chosen by visual inspection). For antigen-based clustering, only the 50 antigens present in the largest numbers of donors were used. 47 of the 61 donors, spread across the three large clusters, had HLA typing available. Association of each HLA with each antigen-based cluster was assessed with a one-sided Fisher's Exact Test, using all available HLA typing.

Enhanced TCR Sequence Discovery and Classification from Case / Control studies: {#S16}
-------------------------------------------------------------------------------

Public TCRβ amino acid sequences ("enhanced sequences") were associated with SARS-CoV-2 infection as described previously ([@R10]). Briefly, one-tailed Fisher's exact tests were performed on all unique TCR sequences comparing the presence in SARS-CoV-2 positive samples with negative controls. Unique sequences were defined by their V gene, J gene, and CDR3 amino acid sequence. For subjects with longitudinal sampling, only the latest available sample was used.

Enhanced sequences were turned into a classifier predicting current or past infection with SARS-CoV-2 using a simple two feature logistic regression with dependent variables E and N, where E is the number of unique TCRβ DNA sequences that encode an enhanced sequence and N is the total number of unique TCRβ DNA sequences in that subject.

The significance threshold used to define the enhanced sequence set was chosen to maximize out-of-sample classification accuracy using 5-fold cross validation. In all cases described, the model identified p\<0.001 as an optimal threshold, though the results were largely insensitive to the specific threshold chosen (data not shown).

The breadth and depth of a disease-specific T-cell response {#S17}
-----------------------------------------------------------

To summarize the extent to which a set of sequenced T cells is specific to a disease or set of antigens, we define the quantities clonal breadth *B* and clonal depth *D* as follows. For a given repertoire *j*, let *N~j~* be the number of unique TCR DNA sequences in the repertoire; *t~ij~, i* = 1, ... , *N~j~*, be the estimated number of T cells that have TCRβ DNA sequence *i* (assumed to derive from the same progenitor cell); and *M~j~* = Σ*~i~t~ij~* be the total number of T cells sequenced by the assay.

Then, for a given set of sequences $\mathcal{D}$, the *clonal breadth of j with respect to* $\mathcal{D}$ is defined to be $N_{j}^{- 1}\sum_{i \in \mathcal{D}}I(t_{ij} > 0)$, where *I* is the indicator function and the summation is over all clones in $\mathcal{D}$. That is, clonal breadth is the proportion of lineages in the repertoire that are mapped to the disease as defined by $\mathcal{D}$.

Clonal depth is similar, but attempts to capture the extent of clonal expansion of each lineage. Because the observed number of DNA templates derived from the same progenitor clone, *t~ij~*, is the result an exponential growth process, we use as our base measure of depth a number that is proportional to the estimated number of clonal generations that lineage *i* went through, *g~ij~* = log~2~(1 + *t~ij~*). Then the *clonal depth of j with respect to* $\mathcal{D}$ is defined to be $\sum_{i \in \mathcal{D}}g_{ij} - \log_{2}(M_{j})$, which estimates the relative number of clonal expansion generations across the TCRs in $\mathcal{D}$, normalized by the total number of TCRs sequenced in the assay.

Error estimates on clonal breadth are derived starting from the assumption of Poisson error on the counting statistics comprising both the numerator $\sum_{i \in \mathcal{D}}I(t_{ij} > 0)$ and denominator *N~j~*. For clonal breadth, the full error on the quotient quantity $B = N_{j}^{- 1}\sum_{i \in \mathcal{D}}I(t_{ij} > 0)$ is then given by $\delta B = B\sqrt{\frac{1}{N_{j}} + \frac{1}{\sum_{i \in \mathcal{D}}I(t_{ij} > 0)}}$.

For clonal depth, errors are estimated starting from the same assumption of Poisson counting errors on both template counts for individual clones *t~i~* as $\delta t_{i} = \sqrt{t_{i}}$ and on total templates *M~j~* as $\delta M_{j} = \sqrt{M_{j}}$. This error is then propagated along to *g~ij~* as $\delta g_{ij} = \frac{\sqrt{t_{i}}}{(1 + t_{i}) \ast \log\, 2}$. Adding in quadrature the errors on the *g~ij~* along with the error on the normalization term *δ* log~2~ $M_{j} = \frac{\sqrt{M_{j}}}{M_{j}\,\log\, 2}$ gives the final uncertainty in the depth as $\delta D = \sqrt{\sum_{i \in \mathcal{D}}(\delta g_{ij})^{2} + (\delta\,\log_{2}\, M_{j})^{2}}$.
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![Magnitude and immunodominance of T-cell response to hundreds of potential SARS-CoV-2 antigens.\
Panel (a) shows the count of identified TCRs across experiments at each antigen position in the viral genome, and Panel (b) shows a similar representation for the count of subjects that had at least 1 TCR identified in the data at that antigen position. The blue bars represent these counts while the gray background indicates the areas covered by the tested antigens. Panel (c) shows the proportion of individuals with a given HLA that respond to a given antigen, restricting to immunodominant antigens. For this figure, we define *response* to mean a MIRA experiment using a subject who expresses the given HLA and for which the number of identified TCRs are more than 2-fold higher than the median number observed for experiments with donors who do not express the HLA. Only HLAs that are observed in at least ≥5 donors are considered, and only HLA-antigen pairs with at least 50% response rates and significant median-fold enrichment are shown. Note that no correction was made for HLA linkage disequilibrium. Detailed data and significance tests are available in [Table S2](#SD1){ref-type="supplementary-material"}. The eleven open reading frames from the virus are indicated below the plots including extra notation for the sixteen nonstructural proteins (nsp) encoded by ORF1ab.](nihpp-2020.07.31.20165647-f0001){#F1}

![Patterns of antigen-TCR reactivity reveal immunodominance of some antigens.\
These two panels show clustergram plots of the (a) protein-level and (b) antigen-level signals across subjects. Each of the rows in the plot represents a distinct subject from the MIRA experiments; the left side label shows coloration for the top five subject clusters. In panel (a), the columns represent the 11 viral proteins in viral genome order. In panel (b), the columns represent the 50 antigens having the most donors with 1 or more TCRs reacting to them. They are sorted in viral genome order and colored by protein at the top. (Note that clustering is done independently for each panel to show the five farthest-separated clusters, and subject sets will vary by color across panels.)](nihpp-2020.07.31.20165647-f0002){#F2}

![Public enhanced sequences associated with SARS-CoV-2 infection distinguish cases from controls.\
Panels (a) and (b) show the number of TCRβ DNA sequences in a subject that encode a SARS-CoV-2 enhanced sequence versus the total number of unique TCRβ DNA sequences sampled from that subject for a large number of cases and controls. Panel (a) represents the training set to identify this initial enhanced sequences list (DLS and NIH/NIAID cohorts), and panel (b) represents a hold-out set with no overlap with the training set (ISB, H12O and BWNW cohorts). Both panels show a similar number and separation of enhanced sequences in cases versus controls.](nihpp-2020.07.31.20165647-f0003){#F3}

![Clonal breadth and depth of the SARS-CoV-2 specific T cell response can be estimated from MIRA-based profiling and from public enhanced sequences.\
Panel (a) is focused on breadth and shows a scatterplot of the relative fraction of the unique TCRβ DNA sequences in the repertoire that are assigned as MIRA or enhanced sequence TCRs. Panel (b) is focused on depth and shows a scatterplot of the summed logarithm of productive template counts across all SARS-CoV-2 associated clones from the two approaches, normalized by subtracting the logarithm of total template counts across all clones. In both panels, error bars on x and y represent the standard deviation.](nihpp-2020.07.31.20165647-f0004){#F4}

![Breadth and depth of the immune response during SARS-CoV-2 infection and after recovery.\
Panels (a) and (b) represent, by time from diagnosis by a viral RT-PCR test, the clonal breadth (relative number of enhanced sequences observed) (a) and depth (a measure of frequency based on the summed logarithm of productive template counts normalized by subtracting the logarithm of total template counts) (b).](nihpp-2020.07.31.20165647-f0005){#F5}

###### Performance of a diagnostic model trained on all available data for 784 cases and 2,458 controls at 99.8% specificity.

Five-fold cross-validation is used to assess the performance.

  ------------------------------------------------------------------
  All @ 99.8% Specificity           \% Sensitivity\    \# Subjects
                                    (with 95% CI)      
  --------------------------------- ------------------ -------------
  **Days since diagnosis:**                            

  0-2                               66.5 (60-72.8)     213

  3-7                               83.8 (77.6-89.4)   174

  8-14                              92.4 (87.6-96.6)   120

  15-28                             93.1 (86.9-97.7)   88

  29-42                             98.1 (92.3-100)    52

  43+                               100 (100-100)      20

  **Days since end of symptoms:**                      

  0-30                              88.9 (62.5-100)    9

  31-60                             95.5 (85.0-100)    22

  61+                               94.4 (80.0-1.0)    18
  ------------------------------------------------------------------

[^1]: These authors contributed equally to this work
